Environmental Toxin Neuroscience · · 25 min read · By

Dihexa for Mould & Mycotoxin Brain Fog: CIRS, Water-Damaged Buildings, Awaab’s Law & the 2026 UK Review

“Ever since we noticed the black patches on the bathroom wall, I can’t think straight.” Damp and mould are not a cosmetic problem. In 2023–24, around 1.3 million English homes (5%) had a damp problem — the highest level in at least five years — and in October 2025 Awaab’s Law came into force, legally compelling social landlords to fix dangerous damp and mould fast. Alongside the well-established respiratory harms, a growing body of research links mould and mycotoxins to neuroinflammation and the forgetful, slowed-down, can’t-find-the-word state people call brain fog. That has driven a wave of interest in whether anything can lift the cognitive aftermath — and Dihexa, a positive modulator of the HGF/c-Met synaptogenesis pathway, keeps appearing in the conversation. This 2026 UK review walks through the damp-housing picture, the inflammasome-and-hippocampus biology, the contested world of CIRS and “toxic mould illness”, and where Dihexa actually sits in the evidence hierarchy. The short version: mechanistically interesting, clinically unproven, and pointless — even risky — if the mould itself is still in the building.

Not medical advice. Dihexa (PNB-0408) is an unscheduled research chemical, not an approved treatment for mould exposure, mycotoxin illness, CIRS, brain fog or any other condition. Nothing on this page is medical advice. The single most important action for mould-related symptoms is to remove the source of damp and mould and improve ventilation; renters in social housing now have protections under Awaab’s Law. People with persistent symptoms should be assessed by their GP. Read the full legal disclaimer.

Key Findings: Dihexa & Mould / Mycotoxin Brain Fog

  • Scale: ~1.3 million English homes (5%) had a damp problem in 2023–24, a 5-year high; privately rented and local-authority homes were worst affected (~9% each).
  • The news hook: Awaab’s Law came into force on 27 October 2025, forcing social landlords to investigate significant damp and mould within 10 working days — with further phases in 2026–27.
  • Established harms: The WHO (2009) found occupants of damp/mouldy buildings have up to a 75% greater risk of respiratory symptoms and asthma; mould also affects the immune system.
  • The cognitive biology: A 2020 Brain, Behavior, and Immunity study showed inhaled mould spores raised hippocampal IL-1β, cut hippocampal neurogenesis and caused memory deficits in mice. Reviews describe NLRP3 inflammasome activation and blood-brain-barrier disruption.
  • The contested part: Brain fog after genuine heavy mould exposure is plausible and partly evidenced; the wider commercial “toxic mould illness” / CIRS model is not a mainstream NHS diagnosis and its markers are weakly validated.
  • Overlap: Mould-related fog shares a final common pathway — immune activation and neuroinflammation — with ME/CFS, long COVID, fibromyalgia and the gut-brain axis.
  • Where Dihexa fits: Neuroinflammation suppresses the BDNF-driven synaptic plasticity Dihexa’s HGF/c-Met mechanism plausibly supports. See mechanism of action. Closest clinical relative: fosgonimeton (ATH-1017), which missed its Alzheimer’s Phase 3 endpoint in 2024.
  • Human mould evidence for Dihexa: None. No registered or published clinical trial of Dihexa in any mould-exposed or mycotoxin population.
  • Specific red flag: Some mycotoxins are carcinogenic (aflatoxin B1 is a human liver carcinogen). Amplifying the pro-proliferative c-Met pathway during possible mycotoxin exposure is a pointed, avoidable theoretical risk.
  • Bottom line: Remove the mould, ventilate, exclude other causes, correct deficiencies, protect sleep and give time. Symptoms usually improve once exposure ends. Dihexa is mechanistically coherent and clinically unproven for mould brain fog — and worse than useless if you’re still breathing the spores.

Mould & Mycotoxin Brain Fog in 2026: Where the UK Stands

For years, damp and mould in British homes were treated as a tenant’s housekeeping problem — wipe it off, open a window, stop drying washing indoors. The death of Awaab Ishak ended that complacency. In 2020 the two-year-old died after prolonged exposure to mould in his family’s housing-association flat in Rochdale; a coroner concluded the mould had caused his death. The fallout reframed damp and mould as a genuine health hazard and drove the legislation that now bears his name.

The scale of the problem is not trivial. According to the English Housing Survey 2023–24, around 1.3 million dwellings (5%) had a damp problem present in one or more rooms — the highest figure in at least five years, up from the 3–4% recorded across the preceding years. Damp was most common in privately rented and local-authority homes (both around 9%), with owner-occupied homes least affected (around 4%). Broader estimates of UK households living with some form of damp or mould run into the millions. The UK Health Security Agency now runs a dedicated programme on the burden of disease caused by damp and mould in English housing.

The well-established harms are respiratory. The World Health Organization’s 2009 indoor-air-quality guidelines concluded that occupants of damp or mouldy buildings have up to a 75% greater risk of respiratory symptoms and asthma, and that around 13% of childhood asthma in the developed world could be attributable to damp housing. The NHS notes that damp and mould raise the risk of respiratory problems, infections, allergies and asthma, and can affect the immune system — with babies, children, older people and the immunosuppressed most vulnerable.

What is newer, and what brings people to a page like this, is the cognitive complaint: a persistent fog — forgetfulness, slowed processing, difficulty concentrating, word-finding lapses — that some people report alongside fatigue, headaches and low mood after living or working in a mouldy building. The same self-experimentation culture that has formed around brain fog in long COVID, Lyme disease and ME/CFS has surfaced Dihexa as a candidate for “mould brain fog” too. The question this article takes seriously is whether the science supports that step — or whether, for almost everyone, the unglamorous answer is the right one: get rid of the mould first.

The 2026 Biology of Mould & Mycotoxin Brain Fog

Brain fog after mould exposure is not a single thing, and it is important to separate what is well-supported from what is speculative. Several mechanisms are plausible, and they operate in parallel.

For evidence-graded longevity and neuroprotection research relevant to this condition, see the Longevity Stack research library.

Innate Immune Activation and the NLRP3 Inflammasome

The dominant model is immune. Mould spores, fragments and the mycotoxins they produce are recognised by the innate immune system. Reviews describe mycotoxins activating the NLRP3 inflammasome, a key intracellular trigger of inflammation, increasing systemic inflammatory cytokines that can in turn disrupt the integrity of the blood-brain barrier — allowing further inflammatory mediators access to brain tissue. A 2023 review in the Journal of Integrative Neuroscience and a 2025 review in OBM Neurobiology both frame neuroinflammation as the central route from mould exposure to cognitive symptoms.

The Hippocampus and Lost Neurogenesis

The most striking mechanistic evidence comes from a 2020 study in Brain, Behavior, and Immunity by Harding and colleagues. Mice given intranasal doses of Stachybotrys (“black mould”) spores — both intact toxic spores and extracted, non-toxic spores — showed increased interleukin-1β in the hippocampus, reduced hippocampal neurogenesis in the dentate gyrus, and striking contextual-memory deficits. Crucially, the level of hippocampal immune activation correlated with the loss of neurogenesis and the memory deficits. The hippocampus is central to memory and learning, unusually sensitive to inflammatory signalling, and — relevantly for the Dihexa question — one of the regions where the HGF/c-Met synaptogenesis system and BDNF-driven plasticity remain active in adulthood. The anatomy of the deficit overlaps with the anatomy of the proposed mechanism.

Oxidative Stress and Mitochondrial Dysfunction

Mycotoxins are lipophilic and can cross the blood-brain barrier, where they are described as damaging astrocytes and generating oxidative stress. Oxidative stress and mitochondrial dysfunction are recurring themes in the fatigue and energy-limited quality of mould-related symptoms — and, as with post-viral syndromes, this is a mechanism Dihexa does not address. A synaptogenic peptide does nothing for cellular energy metabolism, oxidative load or the underlying toxic exposure.

Allergy, Sleep and Mood

Not all “mould fog” is direct neurotoxicity. Mould drives allergic and respiratory symptoms, disrupts sleep, and a damp, anxiety-provoking home situation lowers mood — each of which independently impairs cognition. Disentangling a direct neuroinflammatory effect from poor sleep, allergic misery and the stress of an unhealthy home is genuinely difficult, and it matters: these contributors are addressable without any experimental compound.

The simplified picture. Mould and mycotoxins trigger innate immune activation and NLRP3-inflammasome signalling, raising cytokines that disrupt the blood-brain barrier and drive hippocampal neuroinflammation; this reduces neurogenesis and BDNF-supported synaptic plasticity, while oxidative stress and mitochondrial dysfunction add an energy-limited, fatigued quality, and disturbed sleep, allergy and low mood compound the deficit. Effective recovery removes the exposure and addresses the modifiable parts — the inflammation typically settles once the trigger is gone.

CIRS, “Toxic Mould Illness” & the Controversy

No honest review of this topic can skip the elephant in the room: a large, commercially active ecosystem of “mould illness” testing and treatment that sits well outside mainstream medicine.

The central concept is CIRS — chronic inflammatory response syndrome, a model proposed by the US physician Ritchie Shoemaker. It describes a chronic, multi-system inflammatory illness said to be triggered by biotoxins from water-damaged buildings in genetically susceptible people — specifically those with certain HLA-DR immune-gene types who, the model argues, cannot clear the toxins efficiently. Proponents diagnose CIRS using a cluster of symptoms plus markers such as visual contrast sensitivity, melanocyte-stimulating hormone (MSH), TGF-β1, C4a and MMP-9, and treat it with binders (such as cholestyramine), antifungals and building remediation.

Here is the careful framing. The underlying biology — that mould and mycotoxins can drive immune activation and neuroinflammation — is plausible and partly evidenced, as the section above sets out. But CIRS as a defined clinical syndrome is not a widely recognised NHS or mainstream specialist diagnosis. Its diagnostic markers and protocols have limited independent validation, the symptom list is so broad that it overlaps with many other conditions, and the testing-and-supplement model around it has obvious commercial incentives. Critics argue it risks giving a single, monetisable label to a heterogeneous group of people, some of whom have genuine mould exposure and some of whom have other treatable conditions being missed.

We describe CIRS here for completeness because anyone researching “mould brain fog” will encounter it within minutes — not as an endorsement. The sensible reading in 2026: take genuine, heavy mould exposure seriously, get the building assessed and remediated, and see a doctor for persistent symptoms; be cautious about expensive testing panels and protocols that promise to “detox” mould illness, and be especially cautious about layering an unlicensed peptide on top of an already unproven treatment model.

Awaab’s Law and the 2025–2026 UK News

The reason mould is high in the UK news agenda — and the most relevant recent development for anyone reading this — is Awaab’s Law.

  • What it is. Named after Awaab Ishak, Awaab’s Law sets legally binding timeframes for social landlords in England to deal with hazards, with damp and mould first in scope. The first phase came into force on 27 October 2025.
  • The timeframes. From that date, social landlords must investigate potential emergency hazards and carry out safety work within 24 hours; investigate potential significant hazards (including significant damp and mould) within 10 working days; provide a written summary of findings to the tenant within 3 working days; and begin relevant safety work within strict limits (around 5 working days for confirmed significant hazards). Housing charity Shelter has published a plain-English explainer.
  • What’s next. The duties are due to expand to cover a wider range of hazards in October 2026 and again in 2027, broadening protections beyond damp and mould.

The practical message for the cognitive question is direct. If your brain fog is genuinely linked to mould in a rented home, the most powerful “treatment” available in 2026 is not a peptide — it is reporting the problem and, in social housing, holding your landlord to their new legal duties to fix it. The serious response to mould is environmental and legal, and it is increasingly enforceable.

The Overlap with ME/CFS, Long COVID, Fibromyalgia & the Gut

Mould-related fog does not sit in isolation. It overlaps heavily with the broader family of fatigue-and-fog syndromes, because they share a final common pathway: immune activation, neuroinflammation, disturbed energy metabolism and central sensitisation.

A damp, mouldy environment can worsen symptoms in someone who also has ME/CFS, long COVID or fibromyalgia, and mould exposure is sometimes proposed as a trigger or perpetuating factor for these conditions. The honest position is that the overlap is real but the causal arrows are hard to draw with confidence; the practical implication is to check the home environment as part of the work-up, not to assume mould is the sole driver. There is also a plausible gut-brain dimension: mycotoxins are ingested as well as inhaled, and the gut is a major interface for immune activation.

For the Dihexa question, the overlap cuts two ways. It widens the population searching for cognitive help (and therefore the audience tempted by unlicensed peptides), and it underscores how much of the underlying biology is shared, unresolved and not addressed by a synaptogenic peptide. Dihexa does not touch ongoing toxic exposure, immune dysregulation or mitochondrial energy failure — the mechanisms that actually drive these syndromes.

Where Dihexa Enters: The HGF/c-Met & BDNF Synapse Story

To understand why anyone considers Dihexa here at all, you have to follow the mechanism to the one place it overlaps with mould-related fog: the synapse.

Inflammatory and oxidative states reduce the brain’s capacity to build and maintain dendritic spines — the tiny protrusions where excitatory synapses form. BDNF (brain-derived neurotrophic factor), the master regulator of activity-dependent plasticity, supports spine maturation through its TrkB receptor, and BDNF signalling is suppressed by chronic inflammation. Independently, hepatocyte growth factor (HGF) acting on its receptor c-Met drives synaptogenesis through the PI-3K/AKT and MAPK pathways — a parallel route to the same cellular output. Peak MET expression in the cortex coincides with periods of rapid synaptogenesis, and the system stays active in the adult hippocampus and prefrontal cortex — exactly the regions implicated in mould-related cognitive symptoms.

Dihexa — a small peptide analogue derived from angiotensin IV — is a positive modulator of the HGF/c-Met pathway, a mechanism characterised in the Benoist 2014 JPET study and detailed on the mechanism of action page. The relevance to mould brain fog rests on three points of overlap:

  • Same target tissue. Mould-driven neuroinflammation hits the hippocampus, where HGF/c-Met and BDNF plasticity are active in adults.
  • Same end-point. The deficit is, in part, reduced synaptic and neurogenic capacity — the very output HGF/c-Met signalling supports.
  • A pre-clinical signal, not a clinical one. Dihexa’s synaptogenic effects are demonstrated in animal and cell models of cognition; there is no human trial in mould exposure, mycotoxin illness or any environmental-toxin syndrome.

That third point is the whole ballgame. A coherent mechanistic story is necessary but nowhere near sufficient. It tells you where to look for an effect; it does not tell you that the effect exists, is safe, or outweighs the risks in a person who may still be inhaling spores.

Remove the Exposure First: The Evidence-Based Foundation

If there is one message to take from this page, it is this: for mould-related symptoms, the intervention with the best evidence is ending the exposure. The WHO’s central recommendation is the prevention or minimisation of persistent dampness and microbial growth; the NHS advice is to address the source of moisture and remove mould safely.

In practice that means: find and fix the source of moisture (leaks, rising or penetrating damp, condensation from poor ventilation); remediate or professionally remove the mould rather than just painting over it; improve ventilation and heating to keep surfaces above dew point; and, if you rent, report it in writing to your landlord — who, in social housing, now has enforceable duties under Awaab’s Law. Symptoms commonly improve once the exposure ends, which is both the most encouraging fact in this whole area and the strongest argument against reaching for a peptide while the mould is still there.

Alongside removing the exposure, the same “treat the treatable” logic that runs through this site applies. Persistent fog deserves a GP assessment to exclude the common, cheap, correctable imitators: B12 deficiency, iron deficiency and anaemia, vitamin D deficiency, thyroid disease, poor sleep, depression and anxiety. These are addressable without any experimental compound, and missing one of them while chasing a mould-detox protocol is a real and common error.

The Fosgonimeton Parallel: A Cautionary Tale

The closest thing to a clinical-stage test of the Dihexa mechanism is fosgonimeton (ATH-1017), developed by Athira Pharma as a small-molecule positive modulator of the HGF/MET system — conceptually the same lever Dihexa pulls. It reached Phase 3 in Alzheimer’s disease.

In 2024, the pivotal LIFT-AD trial reported that fosgonimeton missed its primary endpoint. A purpose-built, professionally developed HGF/MET modulator, taken through rigorous trials, failed to show the hoped-for cognitive benefit in its target population. That does not prove the pathway is worthless — trials fail for many reasons — but it is a sobering data point for anyone assuming an unregulated peptide bought online will deliver what a Phase 3 drug could not. If the best-resourced clinical test of this exact mechanism came up short, confident claims about Dihexa clearing mould brain fog should be treated with deep scepticism.

Mould-Specific Risks: The c-Met & Carcinogen Concern

Every page in this series carries the general safety caveats for an unstudied peptide: an unknown long-term safety profile, no pharmaceutical-grade manufacturing or quality control, and a pro-proliferative mechanism. Mould adds a specific wrinkle.

Some mycotoxins are genotoxic and carcinogenic. Aflatoxin B1, produced by Aspergillus species, is a recognised human liver carcinogen; ochratoxin A and others are flagged as possible carcinogens. Dihexa activates the HGF/c-Met pathway, which is pro-proliferative and oncogenically relevant across many tumour types. Pharmacologically amplifying a pro-growth signalling pathway in a person who may have ongoing exposure to genotoxic mycotoxins is a specific, avoidable theoretical risk — conceptually similar to the concern we raise for EBV, an oncogenic virus. No safety study has examined Dihexa in any mould-exposed or mycotoxin-exposed population, so this risk cannot be quantified or excluded — only avoided.

Who Should Not Consider It

Beyond the general contraindications, particular caution applies for mould-related symptoms. Dihexa should not be considered by:

  • Anyone with a personal or family history of cancer — particularly liver cancer, given the aflatoxin link — or other hormone-sensitive or proliferative conditions.
  • Anyone who is immunosuppressed, in whom both serious mould infection and the consequences of a pro-growth signal carry added risk.
  • Anyone with ongoing, unremediated mould exposure — where the entire priority is removing the source, not adding a compound.
  • Anyone who is pregnant or breastfeeding.
  • Anyone with a diagnosed bipolar or psychotic-spectrum condition.
  • Anyone whose symptoms have not been formally assessed by a clinician.

Evidence-Based Care for Mould Brain Fog

The mainstream pathway is unglamorous and effective. Identify and remove the source of damp and mould; ventilate, heat and dry the building; remediate professionally where the affected area is large or the mould is extensive. Report rented-property mould to the landlord in writing and, in social housing, invoke Awaab’s Law timeframes if they do not act. See a GP for persistent symptoms, and ask them to exclude the treatable imitators above. Protect sleep, support mood, and give the inflammation time to settle — which, once the trigger is gone, it usually does. None of that requires an experimental peptide, and all of it is safer.

Practical Realities If You’re Going to Research Dihexa Anyway

This site exists because people research Dihexa regardless, and we would rather they did so with accurate information. If that is you, the honest framing is: do not treat Dihexa as a substitute for remediating the building or for medical assessment; recognise that there is no human evidence in mould or mycotoxin illness and a specific carcinogen-adjacent concern; read the side effects, dosage and UK legal status pages in full; and be honest that the strongest, cheapest and safest intervention available — ending the exposure — is the one a peptide cannot provide. The Dihexa Review 2026 and stacking guide set out why most stacks need clinician oversight.

The Bottom Line

Mould and damp are a serious, under-recognised health issue affecting more than a million English homes, and the cognitive complaint — mould brain fog — has a plausible, partly evidenced biology: innate immune activation, NLRP3-inflammasome signalling, blood-brain-barrier disruption and reduced hippocampal neurogenesis. That biology overlaps neatly with where Dihexa’s HGF/c-Met and BDNF mechanism operates, which is why the peptide keeps appearing in the conversation. But mechanistic overlap is not evidence of benefit; there is no human trial of Dihexa in mould or mycotoxin illness; the closest clinical relative failed its Alzheimer’s Phase 3; and the carcinogenic potential of some mycotoxins makes amplifying a pro-proliferative pathway a pointed concern. Above all, a peptide does nothing about the actual cause. Remove the mould, ventilate, exclude other causes, and give it time — that is the intervention with the evidence, the law, and common sense behind it.

Frequently Asked Questions

Can Dihexa help mould or mycotoxin brain fog?

There is no clinical trial of Dihexa in mould exposure, mycotoxin illness or CIRS. The mechanistic case is coherent — mould-driven neuroinflammation reduces hippocampal neurogenesis and BDNF-supported plasticity, and Dihexa modulates the HGF/c-Met synaptogenesis pathway — but mechanistic plausibility is not proven efficacy, and a peptide does nothing about ongoing exposure to a water-damaged building. Remove the source of mould and see a GP first.

Does mould really cause brain fog?

The respiratory and allergic harms of mould are firmly established. The cognitive effects are biologically plausible and supported by animal and some human data — a 2020 study showed inhaled mould spores raised hippocampal IL-1β, cut neurogenesis and caused memory deficits in mice. What remains contested is the wider commercial “toxic mould illness” / CIRS model, which is not a mainstream NHS diagnosis. Brain fog after genuine heavy exposure is real; the illness industry around it is controversial.

Is CIRS a real diagnosis?

CIRS (chronic inflammatory response syndrome) is a model proposed by Ritchie Shoemaker linking water-damaged-building biotoxins to chronic multi-system illness in genetically susceptible people. The underlying idea that mould can drive immune activation is plausible, but CIRS as a defined syndrome is not widely recognised in NHS or mainstream specialist practice, and its diagnostic markers have limited independent validation. Take genuine exposure seriously; be cautious about expensive testing panels and “detox” protocols.

What is Awaab’s Law?

Awaab’s Law is named after Awaab Ishak, a two-year-old who died in 2020 after prolonged mould exposure in his family’s social housing. Its first phase came into force on 27 October 2025, requiring social landlords in England to investigate significant damp and mould within 10 working days, provide a written summary within 3 working days, and complete safety work within strict timeframes, with further phases in 2026–27. If your fog is linked to rented-home mould, this is the most powerful tool available — not a peptide.

Why is the cancer concern relevant with mould?

Because some mycotoxins are carcinogenic — aflatoxin B1 (from Aspergillus) is a recognised human liver carcinogen, and ochratoxin A is flagged as a possible carcinogen. Dihexa activates the pro-proliferative HGF/c-Met pathway. Amplifying a pro-growth signal in someone who may have ongoing exposure to genotoxic mycotoxins is a specific, avoidable theoretical risk. No safety study has examined Dihexa in any mould-exposed population.

Will brain fog go away once the mould is removed?

For many people, yes — symptoms commonly improve once the exposure ends, which is the most encouraging fact in this area and the strongest argument for prioritising remediation over any compound. Recovery can take time, and persistent symptoms warrant a GP assessment to exclude other causes such as B12, iron, vitamin D, thyroid problems, poor sleep or low mood.

How common is mould and damp in UK homes?

Around 1.3 million dwellings in England (5%) had a damp problem in one or more rooms in 2023–24 — the highest level in at least five years, up from 3–4% previously — according to the English Housing Survey. Privately rented and local-authority homes were worst affected (both ~9%). The WHO concluded that occupants of damp or mouldy buildings have up to a 75% greater risk of respiratory symptoms and asthma.

Should I take Dihexa instead of getting the mould removed?

No. The evidence-based foundation for recovering from mould-related symptoms is to stop the exposure: fix the source of moisture, remediate or remove the mould, improve ventilation, and — if you rent — report it to your landlord, who in social housing now has legal duties under Awaab’s Law. Taking an unlicensed peptide while continuing to live in a water-damaged building treats a downstream cellular process while leaving the actual driver of the inflammation in place.

Could my ME/CFS, long COVID or fibromyalgia fog actually be mould?

Mould exposure is one of several environmental contributors that can overlap with — or be mistaken for — ME/CFS, long COVID and fibromyalgia, because they share a final common pathway of immune activation, neuroinflammation, fatigue and brain fog. A damp, mouldy home can worsen symptoms in someone who also has one of these conditions. The practical implication is to check the home environment as part of the work-up — not to assume mould is the sole cause or to self-treat.

Is Dihexa legal in the UK for mould or mycotoxin illness?

Dihexa is not a controlled drug under the Misuse of Drugs Act and is not a licensed medicine in the UK. It cannot lawfully be marketed or sold to treat mould illness, mycotoxin exposure, CIRS, brain fog or any other condition under MHRA medicines and advertising regulations. Possession for personal research use sits in a regulatory grey zone explained on the UK legal status page. It is not a substitute for removing the mould and having persistent symptoms medically assessed.

External Authoritative Sources Cited